Fax: (206) 667-5977
Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites
Article first published online: 1 JUL 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 20, pages 4810–4816, 15 October 2010
How to Cite
Fesinmeyer, M. D., Goulart, B., Blough, D. K., Buchwald, D. and Ramsey, S. D. (2010), Lung cancer histology, stage, treatment, and survival in American Indians and Alaska Natives and whites. Cancer, 116: 4810–4816. doi: 10.1002/cncr.25410
- Issue published online: 1 JUL 2010
- Article first published online: 1 JUL 2010
- Manuscript Accepted: 6 APR 2010
- Manuscript Revised: 29 MAR 2010
- Manuscript Received: 9 FEB 2010
- lung cancer;
- health status disparities;
- operative therapy
Studies of lung cancer disparities between American Indians and Alaska Natives (AIANs) and whites have yielded mixed results. To the authors' knowledge, no studies to date have investigated whether race-based differences in histology could explain survival disparities.
Data were obtained on AIANs and whites with lung cancer from the 17 population-based cancer registries participating in the Surveillance, Epidemiology, and End Results (SEER) program from 1973 to 2006. Logistic regression was used to determine whether race and other covariates were associated with histology, stage at diagnosis, and receipt of surgery. Cox regression was used to determine the risk of death associated with race, after adjusting for histology, stage, and other covariates.
Histology, but not race, was found to be associated with stage at diagnosis, and both race and stage were found to be associated with histology. AIANs were less likely to receive surgery than whites, after adjusting for patient and tumor characteristics. Survival improved for both AIANs and whites after 2000, compared with the 1973 through 1999 period, but survival was consistently shorter for AIANs. The association between AIAN race and decreased survival was strongest in the later time period.
Lung cancer histology appears to be associated with tumor characteristics, treatment, and survival. AIAN race is associated with tumor histology, receipt of surgery, and survival. In the future, studies with access to smoking data, patient comorbidity information, and health systems-level data will be able to identify factors responsible for the disparities observed in these analyses. Cancer 2010. © 2010 American Cancer Society.
American Indians and Alaska Natives (AIANs) experience disparities in incidence and survival compared with whites for several cancers,1, 2 However, studies aimed at identifying lung cancer disparities between AIANs and whites have had mixed results. A nationwide study of lung cancer incidence found that incidence and stage at diagnosis did not differ between AIANs and whites, although 42% of AIANs were diagnosed before age 65 years, compared with 30% of whites.3 Another study of AIANs in the Seattle-Puget Sound Surveillance, Epidemiology, and End Results (SEER) registry from 1974 through 1989 observed that lung cancer stage distribution at diagnosis and survival were similar for AIANs and whites.4 A later study using SEER data from 1988 through 1995 noted that AIANs with lung cancer had worse 5-year survival rates than any other racial/ethnic group.5 In terms of differences in tumor characteristics, several studies have observed that the incidence of squamous cell lung cancer is higher in AIANs than whites.3, 5 Because survival differs by histology type,6 race-based differences in histology distribution may be mirrored in survival differences. However, to the best of our knowledge, the relation between histology and survival disparities among AIANs is unknown.
To our knowledge, the existence and magnitude of disparities in lung cancer survival and cancer-directed surgery between AIANs and whites has not been established in a population-based sample. No recent nationwide studies have examined whether lung cancer stage at diagnosis and survival differs between AIANs and whites and whether any differences are related to histology type. Furthermore, the most recent study using SEER data only included patients diagnosed through 1995. These prior studies warrant updating, because the overall survival of lung cancer patients has increased as detection and treatment methods have improved over time.7
To address these knowledge gaps, we analyzed SEER data from 1973 to 2006 to determine whether race, histology, and survival in lung cancer were associated among patients in 2 time periods and to document changes in lung cancer disparities between AIANs and whites over time.
MATERIALS AND METHODS
Lung cancer cases were drawn from the 17 population-based cancer registries participating in the SEER program at any point between 1973 and 2006. The populations under SEER registry surveillance encompass 26% of the US population, including 42% of the AIAN population, and are estimated to include >95% of all incident cancers in their catchment areas.8 All AIAN and white cases diagnosed with lung cancer (International Classification of Diseases for Oncology [ICD-O], codes 33.9-34.9) at age ≥21 years were potentially eligible for inclusion in these analyses.9 We limited our analyses to non-small cell carcinoma cases diagnosed with 1 of 5 histology subtypes, comprised of the following ICD-O histology codes: adenocarcinoma (8140, 8251, 8255, 8260, 8310, 8323, 8480, 8481, and 8570), bronchioloalveolar carcinoma (8250, 8252, and 8253), large cell carcinoma (8012 and 8031), squamous cell carcinoma (8052, 8070, 8071, 8072, 8073, and 8074), and other non-small cell carcinoma (ONSCLC) (8010, 8020, 8022, 8032, 8033, 8046, 8050, 8490, 8550, and 8560).9 Cases with in situ stage, unknown stage, and/or unknown surgery status were also excluded from all analyses.
All analyses were performed using SAS statistical software (SAS Institute Inc, Cary, NC). We compared the distribution of age at diagnosis, year of diagnosis, sex, SEER historic stage, surgery status, and histology between AIANs and whites using a chi-square test. We used multinomial regression to test our hypothesis that race is associated with lung cancer histology type, using adenocarcinoma as the comparison category of the dependent variable. We used multinomial regression to test our hypothesis that race and histology type are predictors of stage at diagnosis, using localized/regional stage as the comparison category of the dependent variable. We used logistic regression models to test our hypothesis that race and histology type are associated with receipt of cancer-directed surgery. Finally, we used Cox regression to test our hypothesis that race and histology type are associated with risk of death. All regression analyses were adjusted for sex, SEER site, and age at diagnosis. In addition, the multinomial regression on histology was adjusted for stage, and the Cox regression analyses were also adjusted for stage and receipt of surgery. To account for advances in treatment for lung cancer, all regression analyses were adjusted for categorical year of diagnosis (1973-1999 and 2000-2006). We also constructed models including a race × time period interaction term to determine whether any association between race and histology differed by time period. This study involved data from deidentified subjects only, and was approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center.
Demographic characteristics for AIANs and whites with lung cancer are detailed in Table 1. AIANs were more likely than whites to be diagnosed before age 60 years (30% vs 23%, respectively; P <.0001), and more likely to be diagnosed with localized or regional stage disease (54% vs 51%, respectively; P = .02). Among patients with regional stage disease, 42% of AIANs and 52% of whites underwent surgery (P <.0001). This disparity extended to patients diagnosed with distant stage disease, with 6% of AIANs and 10% of whites undergoing surgery (P = .004). Finally, the distribution of histology types differed by race (P <.0001); the most common histology type among AIANs was squamous cell carcinoma, comprising 32% of cases, whereas adenocarcinoma was the most frequent histology in whites, comprising 39% of cases.
|Age at diagnosis, y|
|Mean age (SD)||65.11||(10.94)||67.43||(10.94)|
|Year of diagnosis|
|SEER historic stage|
|Surgery, localized/regional cases|
|Surgery, distant cases|
|Large cell carcinoma||59||0.06||13,205||0.07||13,264||0.07|
|Other non-small cell||298||0.28||50,030||0.25||50,328||0.25|
|Squamous cell carcinoma||337||0.32||50,956||0.26||51,293||0.26|
Table 2 displays the association between race and histology group. AIANs were significantly more likely than whites to be diagnosed with ONSCLC (odds ratio [OR], 1.22; 95% confidence interval [95% CI], 1.01-1.48) or squamous cell carcinoma (OR, 1.25; 95% CI, 1.02-1.52) versus adenocarcinoma, and the overall association between race and histology was significant (P = .02). Sex and stage were also found to be significantly associated with histology type among all patients (both P <.0001). Women were more likely to be diagnosed with bronchioloalveolar carcinoma, and less likely to be diagnosed with squamous cell carcinoma than men. Patients diagnosed with distant stage disease were less likely to have bronchioloalveolar, large cell, or squamous cell histologies than patients with localized/regional stage disease.
|ORs and 95% CIs for Histology Type|
|Adenocarcinoma||Bronchioloalveolar Carcinoma||Large Cell Carcinoma||Other Non-Small Cell||Squamous Cell Carcinoma||P|
|AIAN vs white race||1 (reference)||0.64 (0.37-1.09)||1.29 (0.94-1.79)||1.22 (1.01-1.48)||1.25 (1.02-1.52)||.02|
|Age at diagnosis|
|1-y increments||1 (reference)||1.01 (1.01-1.01)||1 (1.00-1.01)||1.02 (1.02-1.02)||1.02 (1.02-1.02)||<.0001|
|Female vs male||1 (reference)||1.46 (1.39-1.53)||0.78 (0.75-0.81)||0.83 (0.81-0.85)||0.52 (0.51-0.54)||<.0001|
|SEER historic stage|
|Distant vs localized/regional||1 (reference)||0.25 (0.23-0.26)||0.91 (0.87-0.94)||1.28 (1.25-1.31)||0.49 (0.47-0.50)||<.0001|
As shown in Table 3, race was not found to be significantly associated with stage at diagnosis, after adjusting for histology, SEER site, time period, and age at diagnosis. However, histology was significantly associated with stage at diagnosis. Patients with bronchioloalveolar carcinoma had a greatly reduced risk of distant state disease at the time of diagnosis compared with patients with adenocarcinoma (OR, 0.25; 95% CI, 0.23-0.26), and less substantial reductions in risk were observed for patients with large cell carcinoma (OR, 0.91; 95% CI, 0.87-0.94) and squamous cell carcinoma (OR, 0.49; 95% CI, 0.47-0.50). Patients with ONSCLC were more likely to be diagnosed at distant stage (OR, 1.28; 95% CI, 1.25-1.31) than patients with adenocarcinoma. We repeated these analyses including a race × histology interaction term, which was not statistically significant (data not shown) and was therefore removed from the model.
|ORa (95% CI)||ORb (95% CI)|
|Distant Versus Localized/ Regional||Surgery Versus No Surgery|
|AIAN vs white||0.92 (0.79-1.07)||0.68 (0.55-0.83)|
|Female vs male||0.88 (0.86-0.90)||1.05 (1.03-1.07)|
|Adenocarcinoma||1 (reference)||1 (reference)|
|Bronchioloalveolar carcinoma||0.25 (0.23-0.26)||3.15 (2.97-3.35)|
|Large cell carcinoma||0.91 (0.87-0.94)||0.57 (0.54-0.59)|
|Other non small cell||1.28 (1.25-1.31)||0.30 (0.29-0.31)|
|Squamous cell carcinoma||0.49 (0.47-0.50)||0.63 (0.61-0.65)|
Table 3 also displays the association between race and histology with receipt of surgery. AIANs were less likely to undergo surgery than whites (OR, 0.68; 95% CI, 0.55-0.83). Histology type was also associated with surgery; patients with bronchioloalveolar carcinoma were more likely to undergo surgery (OR, 3.15; 95% CI, 2.97-3.35) and patients with ONSCLC were less likely to undergo surgery (OR, 0.30; 95% CI, 0.29-0.31) than those with adenocarcinoma. Women were less likely than men to be diagnosed with distant disease (OR, 0.88; 95% CI, 0.86-0.90), and more likely to undergo surgery (OR, 1.05; 95% CI, 1.03-1.07).
Table 4 summarizes results of the survival analysis. Compared with whites, AIANs had an increased risk of death (hazard ratio [HR], 1.09; 95% CI, 1.01-1.19). Histology was found to be significantly associated with risk of death, with the most substantial difference observed in patients with bronchioloalveolar carcinoma, who had an HR of 0.68 (95% CI, 0.66-0.70) compared with those with adenocarcinoma. Statistically significant, but clinically minor, survival differences were observed for large cell carcinoma, ONSCLC, and squamous cell carcinoma. We repeated these analyses including a race × histology interaction term, and then a race × time period interaction term. Neither interaction term was found to be statistically significant (data not shown), and therefore both were removed from the models. Figure 1 displays Kaplan-Meier survival curves for AIANs and whites, stratified by year of diagnosis category. Although both AIANs and whites diagnosed in later years had longer survival times than patients diagnosed in earlier years, whites consistently were found to have longer survival than AIANs in both year of diagnosis categories and across all time points.
|HRa (95% CI)|
|AIAN vs white||1.09 (1.01-1.19)|
|Female vs male||0.85 (0.85-0.86)|
|Bronchioloalveolar carcinoma||0.68 (0.66-0.70)|
|Large cell carcinoma||1.15 (1.12-1.17)|
|Other non small cell||1.10 (1.09-1.12)|
|Squamous cell carcinoma||1.05 (1.03-1.06)|
The goal of these analyses was to determine whether race is associated with lung cancer histology, and whether race and histology are associated with death among lung cancer patients in a population-based sample. We found that AIAN race was associated with lung cancer histology type and survival and that survival time differed according to histology type. Furthermore, the association between AIAN race and lung cancer histology, as well as survival disparities between AIANs and whites, appeared to persist even after adjustment for time period, age, treatment, and stage at diagnosis.
Our observation that histology was associated with stage at diagnosis is in line with the current understanding of lung cancer development and progression. For example, bronchioloalveolar carcinoma was more likely than adenocarcinoma to be diagnosed at an early stage, which is consistent with the slow growth typical of bronchioloalveolar tumors.10 Likewise, we noted that squamous cell tumors were most likely diagnosed at an early stage, congruent with the fact that these tumors often arise near the central airway11 and thus may be symptomatic earlier than tumors in peripheral airways.
Smoking behavior could explain the higher incidence of squamous cell carcinomas noted among AIANs compared with whites. The majority of lung cancers diagnosed among nonsmokers or infrequent smokers are adenocarcinomas or bronchioloalveolar carcinomas.12 The prevalence of smoking in AIANs varies widely by age and tribe,13 but the Nationwide Tobacco Use Supplement to the Current Population Survey (TUS-CPS) found that a higher proportion of AIANs smoke than whites. The 2003 TUS-CPS data demonstrated that, among AIANs, 34% of men and 30% of women were current smokers, compared with 21% of white men and 18% of white women.14 Thus, it is not surprising that the incidence of smoking-related lung cancer histology is also higher in AIANs. Our analyses were unable to account for smoking behavior, because SEER does not collect smoking data, but future studies should address the role of smoking in the race-histology association.
As illustrated in Figure 1, survival time increased from the earlier to later time periods in both AIAN and whites, although survival among AIANs was still shorter. A case-control study in AIANs diagnosed with cancer in Montana from 1984 to 1993 found that AIANs were less likely to undergo surgery than whites, but that survival among lung cancer cases did not vary by race.15 In partial contrast, we observed disparities between whites and AIANs from 1973 through 2006 in both receipt of surgery and risk of death. This survival disparity trend may partially be due to racial disparities in access that changed over time. In the 1970s and 1980s, modern treatments such as advanced radiation techniques, adjuvant chemotherapy, and chemoradiation for regional stage disease and palliative chemotherapy for distant stages did not exist. In recent years, lung cancer survival has increased due to advances in surgical techniques,16-18 the adoption of adjuvant chemotherapy,19-22 the increased frequency of chemotherapy treatment in patients with advanced stages of disease,23 and stage migration due to novel staging methods.24 As medical practice advanced, the existing racial gap in access to treatments may have widened and resulted in the survival disparities observed in recent time periods. More research is required to determine whether AIANs have reduced access to emerging lung cancer treatments compared with whites, and whether any access gap is reflected in survival disparities.
We observed significant associations between sex and lung cancer tumor characteristics and survival. It is interesting to note that, female sex and AIAN race appeared to have opposite associations with lung cancer histology and survival. This is consistent with the hypothesis that smoking behavior and/or smoking-related comorbidities could be associated with histology type and survival, because women tend to smoke less than men, and as noted above, AIANs smoke more than whites.14
This study has several important limitations. Although the SEER database provided a large number of population-based AIAN lung cancer patients, SEER does not collect information regarding smoking behavior, clinical performance status at diagnosis, or treating surgeon experience with regard to lung cancer, all of which are reported to be strongly linked to lung cancer survival.25-28 Survival outcomes also depend on the volume of lung cancer surgeries performed at medical centers and the quality of supportive care for patients recovering from surgery and receiving chemotherapy.28, 29 However, this systems-level information is also not available in SEER. Therefore, although we can document differences in lung cancer histology and survival between AIANs and whites, we cannot determine whether these disparities are caused by race-specific differences in access to quality care, or by race-based differences in the prevalence of comorbid conditions (such as diabetes, smoking behavior, and smoking-related disorders) that may complicate treatment, recovery, and survival.
Although SEER is a good source for cancer data on a large number of AIANs, future studies of the clinical attributes and prognosis of lung cancer in AIANs could supplement SEER data with detailed smoking information, including type of cigarette smoked and pack-years. This enrichment of SEER data could be achieved by administering a survey to rapidly identified lung cancer cases reported to SEER. These studies could also collect data regarding comorbidities to control for the effect of overall health on survival outcomes. In addition, SEER does not capture information concerning tribal membership, which may be associated with health-related behaviors and access to care. Our adjustment for SEER site partially accounts for geographic differences, but is unable to completely account for differences between AIAN tribes. Future studies should include factors related to access to quality care, such as hospital volume and provider experience. These studies could differentiate between biological, access, and behavior-based causes for the observed disparities in survival.
In conclusion, our analyses describe differences in lung cancer histology, treatment, and survival between AIANs and whites. Although both racial groups have experienced improvements in survival over time, survival disparities persist and may be increasing, even after adjusting for stage, histology, and treatment. Future studies should consider patient comorbidities and access to quality care as potential confounders of the association between AIAN race and shortened lung cancer survival.
CONFLICT OF INTEREST DISCLOSURES
Supported by Grant 1UO1 CA114642, Native People for Cancer Control, a Community Networks Program funded by the National Cancer Institute.
- 7SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; Year [serial online]. Available at: http://seer.cancer.gov/csr/1975_2006/. Accessed March 22, 2010., , , et al.
- 8National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program Website [serial online]. Available at: http://www.seer.cancer.gov. Accessed March 22, 2010.
- 9FritzA, PercyC, JackA, et al. (eds). International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
- 11Molecular and cellular pathology of lung cancer. In: PassHI, MitchellJB, JohnsonDH, TurrisiAT, MinnaJD, CarboneDP, eds. Lung Cancer: Principles and Practices. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 235-238., , .
- 14Trends in Smoking Prevalence by Race based on the Tobacco Use Supplement to the Current Population Survey. Bethesda, MD: National Cancer Institute [monograph online]. Available at: http://www.fcsm.gov/07papers/Davis.VII-C.pdf. Accessed March 22, 2010., , .
- 22Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7: 719-727., , , et al.